SWOG S1803

Primary Category:

Treatment Protocols

Disease Category:

Multiple Myeloma

Status:

New, Open

Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

Eligible for screening study DCP 001

Occupational Report & Pregnancy Report consent forms available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consents and for any questions.